LFCR — Lifecore Biomedical Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Lifecore Biomedical, fiscal year end - May 26th, USD millions except per share, conversion factor applied.

	R2020 May 31st	R2021 May 30th	R2022 May 29th	2023 May 28th	2024 May 26th
Period Length:	53 W	52 W	52 W	52 W	52 W
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	160	101	111	103	128
Cost of Revenue
Gross Profit	39.4	38.9	39.1	28	41.9
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	186	111	123	149	137
Operating Profit	-25.9	-9.93	-11.8	-45.5	-8.84
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-30.6	-29.8	-20.7	-63.9	9.51
Provision for Income Taxes
Net Income After Taxes	-21.9	-23.4	-15.5	-64.2	9.33
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-38.2	-32.3	-117	-99.6	12
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-38.2	-32.3	-117	-99.6	12
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.371	-0.119	1.55	-1.22	0.606